Assertio Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ASSERTIO, and when can generic versions of ASSERTIO drugs launch?
ASSERTIO has two approved drugs.
There are ten US patents protecting ASSERTIO drugs.
There are thirty-one patent family members on ASSERTIO drugs in twenty-three countries.
Drugs and US Patents for Assertio
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | AB | RX | Yes | Yes | 8,110,606 | See Plans and Pricing | See Plans and Pricing | |||
Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | AB | RX | Yes | Yes | 8,623,920 | See Plans and Pricing | See Plans and Pricing | |||
Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | 8,097,651 | See Plans and Pricing | Y | Y | See Plans and Pricing | |
Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | 9,827,197 | See Plans and Pricing | Y | See Plans and Pricing | ||
Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | AB | RX | Yes | Yes | 7,884,095 | See Plans and Pricing | See Plans and Pricing | |||
Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | AB | RX | Yes | Yes | 7,939,518 | See Plans and Pricing | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Assertio
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | 6,974,595 | See Plans and Pricing |
Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | 6,287,594 | See Plans and Pricing |
Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | 7,482,377 | See Plans and Pricing |
Assertio | ZIPSOR | diclofenac potassium | CAPSULE;ORAL | 022202-001 | Jun 16, 2009 | 6,365,180 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ASSERTIO drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2012-11-14 |
➤ Subscribe | Potassium Oral Solution (Sachet) | 50 mg | ➤ Subscribe | 2011-01-24 |
International Patents for Assertio Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2006257072 | See Plans and Pricing |
Poland | 1890680 | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 2006133954 | See Plans and Pricing |
Guatemala | 200600261 | See Plans and Pricing |
Ecuador | SP077989 | See Plans and Pricing |
Canada | 2632375 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.